Zydus Lifesciences share price
Zydus Lifesciences Ltd. · NSE: ZYDUSLIFE · Healthcare
Price, one year
Price range
- Open
- ₹1,138.00
- High
- ₹1,143.50
- Low
- ₹1,119.20
- Previous close
- ₹1,135.00
- Volume
- 7.4 L
- Market cap
- ₹1,12,189 Cr
Key statistics
Results to 30 Jun 2026 · Consolidated- P/E (TTM)
- 25.3
- Price to book
- 4.2
- Return on equity
- 16.6%
- EPS (TTM)
- ₹44.87
- Book value / share
- ₹271.79
- Debt to equity
- 0.40
- Revenue (TTM)
- ₹28,592 Cr
- Net profit (TTM)
- ₹4,513 Cr
- Sales growth, YoY
- +22.0%
- Profit growth, YoY
- −35.9%
- Operating margin
- 29.1%
- Net margin
- 15.8%
- Sales CAGR, 3 years
- +16.4%
- Profit CAGR, 3 years
- +37.0%
- Promoter holding
- 75.01%
- Promoter shares pledged
- 0.00%
Shareholding pattern
% of shares| Holder | Jun 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 75.01 | 75.01 | 75.01 |
| Foreign institutions | 6.89 | 6.88 | 7.05 |
| Domestic institutions | 11.19 | 11.27 | 11.28 |
| Mutual funds | 4.92 | 5.12 | 6.88 |
| Retail and others | 5.46 | 5.45 | 5.30 |
Futures and options
22 Oct 2026- Lot size
- 900
- Put-call ratio (OI)
- 0.58
- Max pain
- ₹1,150.00
- Highest call OI strike
- 1,200.00
- Highest put OI strike
- 1,100.00
- ATM implied volatility
- 31.8% IV rank 73
- Futures basis
- +0.19%
- Rollover
- 42.3%
Futures open interest, last sessions
| Date | Build-up | Price | OI change |
|---|---|---|---|
| 22 Oct | Short covering | +1.95% | −8.71% |
| 21 Oct | Long buildup | +0.12% | +8.94% |
| 19 Oct | Short buildup | −1.37% | +4.41% |
| 16 Oct | Short buildup | −1.47% | +6.54% |
| 15 Oct | Long buildup | +1.50% | +0.38% |
Option figures are for the 27 Oct 2026 expiry.
Results and announcements
Latest results (quarter to 30 Jun 2026) filed 11 Aug 2026. results: 4 Nov 2026.
- 21 Oct 2026 · Press releasePress ReleaseZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing...
- 21 Oct 2026 · Press releasePress ReleaseZydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day...
- 16 Oct 2026 · OtherGeneral UpdatesZydus Lifesciences Limited has informed the Exchange about General Updates ESG Rating
Peers in Healthcare
All Healthcare stocks| Company | Price | Change |
|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | ₹1,740.20 | −1.01% |
| Divi's LaboratoriesDIVISLAB | ₹8,882.00 | −3.06% |
| Torrent PharmaceuticalsTORNTPHARM | ₹4,487.50 | −2.77% |
| Apollo Hospitals EnterpriseAPOLLOHOSP | ₹7,579.00 | −0.34% |
| CiplaCIPLA | ₹1,318.90 | −0.90% |
| Laurus LabsLAURUSLABS | ₹1,943.40 | −2.95% |
| Dr. Reddy's LaboratoriesDRREDDY | ₹1,226.10 | −1.04% |
| Mankind PharmaMANKIND | ₹2,229.50 | −2.03% |
| Aurobindo PharmaAUROPHARMA | ₹1,557.50 | −3.31% |
| LupinLUPIN | ₹1,906.60 | −0.80% |
Frequently asked questions
What is the share price of Zydus Lifesciences today?
Zydus Lifesciences (NSE: ZYDUSLIFE) was at ₹1,124.70 on 23 Oct 2026, a change of −0.91% from the previous close.
What are the 52-week high and low of Zydus Lifesciences?
Over the last 52 weeks Zydus Lifesciences traded between ₹835.50 and ₹1,232.10 (daily highs and lows on NSE on 23 Oct 2026).
What is the market capitalisation of Zydus Lifesciences?
About ₹1,12,189 Cr at the latest price, with a P/E of 25.3, a price-to-book of 4.2, a return on equity of 16.6%. Ratios use the company's latest reported results.
Who owns Zydus Lifesciences shares?
According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 75.01%, foreign institutions 7.05%, domestic institutions 11.28%.
Is Zydus Lifesciences traded in futures and options?
Yes, ZYDUSLIFE is in NSE's futures and options segment. The lot size is 900 shares.
Which sector and indices does Zydus Lifesciences belong to?
NSE classifies Zydus Lifesciences under Healthcare; it is a member of Nifty 100, Nifty 500.
Follow Zydus Lifesciences with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.
Get started free